BiotechTube

Linaclotide

Phase 3Completed
1 views this week 0 watching💤 Quiet
Interest: 34/100
34
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Irritable Bowel Syndrome With Constipation

Conditions

Irritable Bowel Syndrome With Constipation, Chronic Constipation

Trial Timeline

Sep 1, 2008 → Mar 1, 2012

NCT ID
NCT00730171

About Linaclotide

Linaclotide is a phase 3 stage product being developed by Ironwood Pharmaceuticals for Irritable Bowel Syndrome With Constipation. The current trial status is completed. This product is registered under clinical trial identifier NCT00730171. Target conditions include Irritable Bowel Syndrome With Constipation, Chronic Constipation.

What happened to similar drugs?

7 of 20 similar drugs in Irritable Bowel Syndrome With Constipation were approved

Approved (7) Terminated (1) Active (13)
✅Ramosetron + PlaceboAstellas PharmaApproved
✅Ramosetron + PlaceboAstellas PharmaApproved
✅duloxetineEli LillyApproved
✅Bacillus clausii + MetronidazoleSanofiApproved
✅Iberogast® and Iberogast® NBayerApproved
✅LinaclotideIronwood PharmaceuticalsApproved
✅Linaclotide + PlaceboIronwood PharmaceuticalsApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT02590432ApprovedCompleted
NCT00765999Phase 3Completed
NCT00730171Phase 3Completed

Competing Products

20 competing products in Irritable Bowel Syndrome With Constipation

See all competitors
ProductCompanyStageHype Score
linaclotide + placeboAstellas PharmaPhase 2
35
YM060 + PlaceboAstellas PharmaPhase 3
40
Ramosetron + PlaceboAstellas PharmaApproved
43
Ramosetron + PlaceboAstellas PharmaApproved
43
YM060Astellas PharmaPhase 3
40
YM060 + placeboAstellas PharmaPhase 2
35
YM060Astellas PharmaPhase 3
40
linaclotide + PlaceboAstellas PharmaPhase 3
40
RamosetronAstellas PharmaPre-clinical
26
YM060Astellas PharmaPhase 2
35
ONO-2952 + Placebo comparatorOno PharmaceuticalPhase 2
27
ONO-2952 + ONO-2952 Matching PlaceboOno PharmaceuticalPhase 2
35
duloxetineEli LillyApproved
43
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) + Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)AbbViePhase 3
40
25mg Eluxadoline + 100mg EluxadolineAbbViePhase 3
47
Eluxadoline + PlaceboAbbViePhase 2
42
Placebo + LinaclotideAstraZenecaPhase 3
40
TegaserodNovartisPre-clinical
26
DNK333NovartisPhase 2
35
SMS995 + PlaceboNovartisPhase 1
29